CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models

Investigational New Drugs

Volumn 32, Issue 6, 2014, Pages 1105-1112

  Kim, Sun Hee ^a   Margalit, Ofer ^b   Katoh, Hiroshi ^b   Wang, Dingzhi ^b   Wu, Hong ^a   Xia, Dianren ^a   Holla, Vijaykumar R ^a   Yang, Peiying ^a   Dubois, Raymond N ^b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Carbonic anhydrase I II; Celecoxib; CG100649; Colorectal cancer; COX 2; PGE2

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; FURAN DERIVATIVE; POLMACOXIB; PROSTAGLANDIN E2; SULFONAMIDE;

ADENOMA; ANIMAL; CARCINOMA; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; MOUSE; TUMOR CELL LINE;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FURANS; HUMANS; MICE; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939884875     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0144-z     Document Type: Article

References (28)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674. doi: 10.1016/j.cell.2011.02.013
2. Wang D, Dubois RN (2012) The role of anti-inflammatory drugs in colorectal cancer. Annu Rev Med. doi: 10.1146/annurev-med-112211-154330
3. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355(9):885-895. doi: 10.1056/NEJMoa061652
4. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131(6):1674-1682. doi: 10.1053/j.gastro.2006.08.079
5. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873-884. doi: 10.1056/NEJMoa061355
6. Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. Jama 302(6):649-658. doi: 10.1001/jama.2009.1112
7. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356(21):2131-2142. doi: 10.1056/NEJMoa067208
8. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107(4):1183-1188
9. Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10(3):181-193. doi: 10.1038/nrc2809
10. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092-1102. doi: 10.1056/NEJMoa050493
11. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-1080. doi: 10.1056/NEJMoa050405
12. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET (2009) Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2(4):310-321. doi: 10.1158/1940-6207.CAPR-08-0206
13. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96(1):272-277
14. Grosser T, Yu Y, Fitzgerald GA (2010) Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 61:17-33. doi: 10.1146/annurev-med-011209-153129
15. Yu Y, Ricciotti E, Grosser T, Fitzgerald GA (2009) The translational therapeutics of prostaglandin inhibition in atherothrombosis. J Thromb Haemost 7(Suppl 1):222-226. doi: 10.1111/j.1538-7836.2009.03439.x
16. Coxib, traditional NTC, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769-779. doi: 10.1016/S0140-6736(13)60900-9
17. Aw TJ, Haas SJ, Liew D, Krum H (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165(5):490-496. doi: 10.1001/archinte.165.5.IOI50013
18. Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA (2012) Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther 91(6):986-993. doi: 10.1038/clpt.2012.3
19. Yang P, Felix E, Madden T, Fischer SM, Newman RA (2002) Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. Anal Biochem 308(1):168-177
20. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN (2000) Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 275(43):33951-33956. doi: 10.1074/jbc.M002324200
21. Sharma RA, Gescher A, Plastaras JP, Leuratti C, Singh R, Gallacher-Horley B, Offord E, Marnett LJ, Steward WP, Plummer SM (2001) Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells. Carcinogenesis 22(9):1557-1560
22. Moser AR, Pitot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247(4940):322-324
23. Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM (2011) C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila) 4(8):1172-1180. doi: 10.1158/1940-6207.CAPR-10-0403
24. Xia D, Wang D, Kim SH, Katoh H, DuBois RN (2012) Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med 18(2):224-226. doi: 10.1038/nm.2608
25. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55(12):2556-2559
26. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55(17):3785-3789
27. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, Windsor AC, Guillou PJ, Markham AF, Coletta PL, Hull MA (2000) Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 156(2):545-553. doi: 10.1016/S0002-9440(10)64759-1
28. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111(2):241-250